Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Depreciation and Depletion (2023 - 2025)

X4 Pharmaceuticals' Depreciation and Depletion history spans 3 years, with the latest figure at $168000.0 for Q2 2025.

  • For Q2 2025, Depreciation and Depletion rose 143.48% year-over-year to $168000.0; the TTM value through Jun 2025 reached $626000.0, up 125.18%, while the annual FY2025 figure was $500000.0, 66.67% up from the prior year.
  • Depreciation and Depletion reached $168000.0 in Q2 2025 per XFOR's latest filing, down from $289000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $289000.0 in Q1 2025 to a low of $43000.0 in Q4 2023.
  • Average Depreciation and Depletion over 3 years is $113000.0, with a median of $84500.0 recorded in 2024.
  • Peak YoY movement for Depreciation and Depletion: dropped 23.08% in 2024, then surged 366.13% in 2025.
  • A 3-year view of Depreciation and Depletion shows it stood at $43000.0 in 2023, then surged by 106.98% to $89000.0 in 2024, then surged by 88.76% to $168000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Depreciation and Depletion are $168000.0 (Q2 2025), $289000.0 (Q1 2025), and $89000.0 (Q4 2024).